Dr. Jonathan Lakey
Professor Emeritus of Surgery & Biomedical Engineering, UC Irvine. Co-inventor of the Edmonton Protocol. Scientific Founder of BioSignal Sciences.
Dr. Jonathan Lakey is Professor Emeritus of Surgery and Biomedical Engineering at UC Irvine, with more than 520 peer-reviewed publications and 50+ invited book chapters spanning diabetes, islet transplantation, stem cell technologies, and biomaterials. He is co-inventor of the Edmonton Protocol — the landmark treatment for Type-1 diabetes via islet transplantation — and brings advanced expertise in cryopreservation alongside several issued and provisional patents. He founded and served as CSO of a pet stem cell therapy company and co-founded a stem cell banking and disease-differentiation transplant company. Globally recognized for leadership in stem cell and exosome-derived therapeutic products, Dr. Lakey provides the scientific foundation for BioSignal Sciences and 4th State Medical's regenerative platform.
- — Co-inventor of the Edmonton Protocol for Type-1 diabetes
- — 520+ peer-reviewed publications and 50+ invited book chapters
- — Advanced cryopreservation methods for cells and tissues
- — Stem cell banking, pet therapeutics, and exosome-derived products
Pilot study of a topical mesenchymal stem cell media–conditioned cream (Neurocream) applied twice daily to the soles of the feet after brief micro-needling in type-2 diabetic and non-diabetic patients with progressive neuropathy. T2D participants reported approximately a 50% average reduction across foot pain, tingling, and swelling at 30 days; non-T2D participants reported a 57% reduction in swelling and 40% reduction in foot pain. All participants reported improved sleep.
Validation of a combinational cryoprotectant strategy using lower-than-conventional concentrations of two permeating agents (DMSO and ethylene glycol) with a stepwise sucrose dilution during recovery. The optimized protocol yielded significantly higher post-thaw MSC viability (~80%) versus conventional DMSO-only approaches, supporting more effective banking of stem cells for downstream therapeutic use.
Pilot clinical trial (n=12) evaluating a topical stem cell–conditioned skin cream applied over eight weeks to address age-related skin concerns including tone, texture, brightness, and fine lines. Discussion covers the biology of skin senescence, paracrine signaling by MSCs, and the growth-factor and cytokine cargo underlying observed improvements in skin aesthetics.
Single-center 30-day clinical study (n=15, ages 18–43) of a topical acne product combining stem cell–conditioned media with salicylic acid. Analysis showed a statistically significant improvement in overall acne lesion appearance from baseline at day 30 (p=0.004) and strong participant-reported improvements in skin texture, with a favorable safety profile.
Comprehensive review of exosome biology across biomarker discovery, therapeutic delivery, and disease-modifying strategies in type-1 diabetes. Covers exosome biogenesis, cargo-mediated cellular crosstalk, autoimmune pathways in β-cell dysfunction, and the translational path toward exosome-based diagnostics and therapies, with implications for type-2 diabetes as well.